Home/ Stocks/ AIM

AIM ImmunoTech Inc.

AIM XASE

$0.97 +0.01 (+1.52%) ▲ 15-min delayed

Open

$0.96

High

$1.05

Low

$0.90

Volume

1.05M

Market Cap

$4.03M

About AIM ImmunoTech Inc.

AIM ImmunoTech Inc is an immuno-pharma company focused on the research and development of therapeutics to treat multiple types of cancers, viral diseases, and immune-deficiency disorders, and to treat cancers for which there are currently inadequate or unmet therapies. Its flagship products are Ampligen (rintatolimod) and Alferon N Injection (Interferon alfa). Ampligen is a double-stranded RNA (dsRNA) molecule being developed for globally important cancers, viral diseases, and disorders of the immune system. Ampligen is approved for commercial sale in the Argentine Republic for the treatment of severe Chronic Fatigue Syndrome (CFS).

Sector: BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) Employees: 23 Website →

Key Financials

Period	Revenue	Net Income	EPS
Q3 2025	$26.0K	$-3,284,000	$1.57
Q1 2025	$16.0K	$-3,705,000	$-0.05
FY 2024	$170.0K	$-17,320,000	$-0.31
Q3 2024	$35.0K	$-3,700,000	$-0.06

Earnings & Analyst Ratings

Next Earnings: Wed, May 13, 2026

Calendar →

Related Market News

No specific coverage for AIM yet. Check out our latest market news or earnings calendar.

Get AIM Alerts

Stay ahead with breaking news, price alerts, and expert analysis on AIM ImmunoTech Inc..

Disclaimer: This page is for informational purposes only. Stock data is delayed by at least 15 minutes. Always conduct your own research and consult with a qualified financial advisor before making investment decisions.